Since 1999, after the SHOCK trial demonstrated a reduction in mortality with early myocardial revascularization in patients with acute myocardial infarction complicated by cardiogenic shock,1 intensive care specialists and interventionalists have searched for additional ways to reduce the persistently high mortality, often in the range of 40% to 50%.2 After other reports demonstrated that intra-aortic balloon pump (IABP) support failed to reduce mortality,3-5 the next step was development and evaluation of other approaches for active mechanical circulatory support, including microaxial left ventricular assist devices (LVADs), in the treatment of cardiogenic shock.
Thiele H, Desch S, Freund A. Microaxial Left Ventricular Assist Devices: In Search of an Appropriate Indication. JAMA. Published online February 10, 2020. doi:10.1001/jama.2019.22382
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: